Pharmacokinetics and pharmacodynamics of a fixed-dose combination of gemigliptin/metformin sustained release 25/500 mg compared to the loose combination in healthy male subjects

A fixed-dose combination (FDC) of gemigliptin/metformin can improve the medication adherence in patients with type 2 diabetes mellitus (T2DM). In this study, the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of gemigliptin and metformin were compared between FDC and the corresponding loose...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Xuanyou, Kim, Eunwoo, Huh, Ki Young, Hwang, Inyoung, Cho, Joo-Youn, Yu, Kyung-Sang, Lee, SeungHwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Clinical Pharmacology and Therapeutics 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136079/
https://www.ncbi.nlm.nih.gov/pubmed/32274380
http://dx.doi.org/10.12793/tcp.2020.28.e2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136079/
https://www.ncbi.nlm.nih.gov/pubmed/32274380
http://dx.doi.org/10.12793/tcp.2020.28.e2

Ejemplares similares